INM

InMed Pharmaceuticals, Inc.

( )

Page Views : 132135

Analyst Ratings

Buy

Strong Buy

0%

Buy

100%

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Sector

:

Healthcare

Industry

:

Biotechnology

Exchange

:

Nasdaq

Ticker

:

INM

vista's key points

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.
InMed has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
InMed is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.
InMed has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative disease such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
InMed's wholly owned subsidiary, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
InMed is considered a low float stock with 1.51Million shares Issued and outstanding according to their latest presentation.

Trade Now

vista's key points

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.
InMed has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
InMed is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.
InMed has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative disease such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
InMed's wholly owned subsidiary, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
InMed is considered a low float stock with 1.51Million shares Issued and outstanding according to their latest presentation.

Sector

:

Healthcare

Industry

:

Biotechnology

Exchange

:

Nasdaq

Ticker

:

INM

company profile

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. They also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.

Unlike natural cannabinoids isolated from the plant which are not patentable, InMed’s proprietary cannabinoid analogs are patentable and are recognized as new chemical entities (NCEs). These analogs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases. They are screening these analogs for their therapeutic properties and pharmaceutical development.

InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. They have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. they currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBT) which are available for B2B purchase.

www.inmedpharma.com.

vista's view

InMed Pharmaceuticals (“InMed”) is a publicly traded company on the Nasdaq that trades under the symbol INM. InMed is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs....

InMed Pharmaceuticals (“InMed”) is a publicly traded company on the Nasdaq that trades under the symbol INM. InMed is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. They also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

InMed pharmaceutical programs include a Phase 2 clinical trial studying the safety and efficacy of cannabinol (CBN) cream for epidermolysis bullosa and preclinical programs in glaucoma and neurodegenerative disease.

InMed’s rare cannabinoids are being applied across a spectrum of uses – from pharmaceutical development to wholesale sales to the consumer health and wellness sector. In addition, a wholly owned subsidiary of InMed, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.

On January 10, InMed issued a press release, which outlined their key accomplishments from 2022 and provided business update and catalysts for 2023 including the following interesting milestones for 2023:

Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023
Progress preclinical research in glaucoma in preparation for human trials
Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s

Eric A. Adams, InMed President and CEO. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how. Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed was able to advance its programs and achieve a number of key milestones. As we move forward into 2023, we are very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters.” Learn More by clicking here to view our latest story regarding this update.

On Nov. 17, Vista Partners’ sister organization Tribe Public hosted a Webinar Presentation and Q&A Event that was co-hosted by Eric A. Adams, CEO & Eric C. Hsu, PhD, Senior Vice President, Pre-Clinical Research & Development of InMed Pharmaceuticals (NASDAQ: INM. They delivered a presentation titled “Exploring The Neuroprotective Qualities of Rare Cannabinoids” & addressed a Q&A session at the end of the presentation. You may now watch the event video that has received over 17,ooo views at the Tribe Public YouTube Channel at this link.

View InMed’s latest powerpoint presentation here.

Read Less